A comprehensive review on artificial intelligence driven approaches for vaccine development: Current advances, challenges, and future prospects - 17/03/26

, Reetesh Kumar bHighlights |
• | AI has revolutionized vaccine development by rapid antigen discovery, epitope prediction and rationale vaccine design. |
• | It enhances vaccine efficacy and safety through structural modelling, adjuvant selection, delivery optimization, and real-time trial monitoring. |
• | Integration of multi-omics data and machine learning accelerates vaccine pipelines and improves scalability and precision. |
• | Responsible and globally accessible AI-driven vaccines require ethical considerations like equity, transparency, bias, and data privacy. |
Abstract |
Artificial intelligence (AI) has emerged as an exemplified tool in the field of modern biomedical technology. The unprecedent COVID-19 pandemic and other infectious disease crises have highlighted the critical need for rapid and accurate vaccine development processes. The traditional method of vaccine development methods are often time-consuming, costly, and inefficient. On contrary to this, the AI streamlines vaccine development from antigen prediction to clinical trial optimization by integrating computational biology, machine learning, structural bioinformatics, and immunoinformatic. AI has many potential applications in vaccine research, and this review covers all of the bases, from the fundamentals of AI in biology to immunogen design, clinical trial data mining, efficacy prediction modelling modelling, and adjuvant optimization. The review also investigates potential unknown issues, ethical concerns, and future developments in AI-driven vaccine development. This paper emphasizes the potential of AI to transform global preparedness against infectious diseases by combining evidence from various disciplines in vaccine development.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Keywords : Artificial Intelligence, Adjuvants, Biomedical technology, Clinical trials, Vaccine
Plan
Vol 74 - N° 2
Article 103577- avril 2026 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
